Abstract
Many patients who receive co-treatment with GnRH agonists (GnRH-a) during chemotherapy treatment preserve their ovarian function and are at risk of unintended pregnancies. Therefore, it is important to offer them effective contraception. Also, pregnancies occurring after cancer therapy in women who received GnRH-a are not associated with adverse neonatal outcomes.
MeSH terms
-
Adolescent
-
Adult
-
Antineoplastic Agents, Hormonal / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Bleomycin / therapeutic use
-
Case-Control Studies
-
Dacarbazine / therapeutic use
-
Doxorubicin / therapeutic use
-
Female
-
Gonadotropin-Releasing Hormone / agonists*
-
Hematologic Neoplasms / complications
-
Hematologic Neoplasms / drug therapy*
-
Hematologic Neoplasms / epidemiology
-
Humans
-
Infant, Newborn
-
Middle Aged
-
Pregnancy
-
Pregnancy Complications, Neoplastic / epidemiology
-
Pregnancy Outcome
-
Pregnancy, Unplanned*
-
Primary Ovarian Insufficiency / prevention & control*
-
Time Factors
-
Triptorelin Pamoate / therapeutic use*
-
Vinblastine / therapeutic use
-
Young Adult
Substances
-
Antineoplastic Agents, Hormonal
-
Triptorelin Pamoate
-
Bleomycin
-
Gonadotropin-Releasing Hormone
-
Vinblastine
-
Dacarbazine
-
Doxorubicin